PTC 治疗技术 与诺华达成10亿美元的交易 用于亨廷顿的疾病治疗 PTC Therapeutics secures $1 billion deal with Novartis for Huntington's disease treatment.

PTC 治疗技术公司已经与诺华公司签订了一项重要协议,用于Huntington的Huntington病治疗PTC518,确保预付10亿美元,今后达到19亿美元的里程碑。 PTC Therapeutics has signed a major deal with Novartis for its Huntington's disease treatment PTC518, securing a $1 billion upfront payment and up to $1.9 billion in future milestones. Novartis将接管全球发展和商业化后的关键研究,同时与PTC分享美国利润。 Novartis will take over global development and commercialization post a key study, while sharing U.S. profits with PTC. PTC的库存在新闻上猛增了15%以上,反映出合作在财政和治疗方面的巨大潜在影响。 PTC’s stock surged over 15% on the news, reflecting the significant financial and potential therapeutic impact of the collaboration.